Bert Chenard

Biography

Bert Chenard joins Hydra with 30 years of industry experience specializing in ion channel and G-protein coupled receptor (GPCR) research. Previously, Dr. Chenard served as Sr. Vice President of Chemistry and Process Research at Neurogen Corp. In this role, he delivered a dozen small molecule development candidates including Adipiplon, a subtype-selective GABA agonist. Prior to Neurogen, Dr. Chenard was a Research Advisor at Pfizer Inc. in a career spanning over 15 years. His research efforts at Pfizer generated several development candidates including Traxoprodil, the first highly selective NR2B antagonist. Dr. Chenard began his career at DuPont's Experimental Station doing exploratory organic chemistry. Here, he discovered several specialized reagents, including TMSOK, which are of general use to synthetic chemists. Dr. Chenard received his B.A. at Central Connecticut State University and a Ph.D. from Ohio State University. He has more than 100 publications and granted U.S. patents. 

Research Interest

Preclinical Development